GenSight Biologics Email Format

Biotechnology ResearchÎle-de-france, France11-50 Employees

GenSight Biologics is a clinical-stage biotechnology company focused on discovering and developing therapies for neurodegenerative retinal diseases and other central nervous system disorders. Its lead candidate GS010 is in Phase III trials for Leber's Hereditary Optic Neuropathy, a rare mitochondrial disorder that can cause irreversible vision loss in teens and young adults. The company pursues a gene therapy-based approach designed to be delivered as a single intravitreal injection per eye, aiming for a sustainable functional vision outcome. Based in Paris, France, GenSight Biologics operates as a small to mid-sized firm within the biotechnology research sector.

In early 2026, the company cited an ongoing collaboration with the 15-20 Hospital as part of its efforts to develop transformative therapies for rare diseases, reflecting its partnerships with medical institutions.

Sign up for free to view info

Company overview Employee directory